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Abstract
Background: Animal and organ culture experiments have shown beneficial inhibitory estrogen
effects on post injury neointima development. The purpose of this study was to investigate whether
such estrogen effects are influenced by the estrogen receptor antagonist ICI 182,780. Different
concentrations of 17β-estradiol and the phytoestrogens genistein and daidzein were tested.
Methods: F emale New Zealand White rabbits were benumbed. In situ vascular injury of the
thoracic and abdominal aorta was performed by a 3F Fogarty catheter. Segments of 5 mm were
randomised and held in culture for 21 days. Three test series were performed: 1) control group –
20 µM ICI – 30 µM ICI – 40 µM ICI. 2) control group – 20 µM ICI – 40 µM 17β-estradiol – 40 µM
17β-estradiol + 20 µM ICI. 3) control group – 20 µM ICI – 40 µM daidzein – 40 µM daidzein + 20
µM ICI – 20 µM genistein – 20 µM genistein + 20 µM ICI. After 21 days the neointima-media-ratio
was evaluated.
Results: 1) Treatment with ICI 182,780 did not reduce neointima formation significantly (p = 0.05).
2) 40 µM 17β-estradiol alone (p < 0.0001) and in combination with 20 µM ICI (p < 0.0001) reduced
neointima formation significantly. 3) 20 µM genistein alone (p = 0.0083) and combined with 20 µM
ICI (p = 0.0053) reduced neointima formation significantly. 40 µM daidzein did not have a significant
(p = 0.0637) effect.
Conclusions: The estrogen receptor antagonist ICI 182,780 did not modulate the inhibitory
estrogen effects on post injury neointima formation. These results do not support the idea that
such effects are mediated by vascular estrogen receptors.
Background
Beneficial estrogen effects in the cardiovascular system are
still under investigation and have been discussed contro-
versially [1–3]. Clinical benefits such as the reduction of
cardiovascular mortality, as suggested by several retro-
spective studies, [4,5] have not been supported by ran-
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domised [6] and interventional [7,8] trials. However,
there are plenty of experimental data demonstrating ben-
eficial estrogen effects on distinct aspects of the cardiovas-
cular system, i.e., lipid metabolism [9] and lipid
peroxidation [10], post injury smooth muscle cell and ne-
ointimal proliferation [11–14], and the vascular tone
[15–18]. Some of these effects are also described for phy-
toestrogens like genistein and daidzein which therefore
may be suggested as a possible therapeutic option in post-
menopausal women [19].
In previous organ culture experiments we have demon-
strated that 17β-estradiol and the phytoestrogens genis-
tein (with) [20] and daidzein (without protein tyrosine
kinase activity) [21] were able to inhibit neointima forma-
tion after vascular injury in a dose dependent manner
[22,23]. These effects have been described in aortic rings
not only from female but from male rabbits as well [24].
In further experiments we titrated the lowest concentra-
tions of these three estrogens which were able to reduce
neointima formation significantly and we moreover dem-
onstrated that this effect was unlikely caused by toxicity
[25].
The aim of this present in vitro study was to investigate
whether the inhibitory estrogen effect on post injury ne-
ointima development is modulated by estrogen receptor
dependent pathways. Such interactions have been dem-
onstrated and postulated since estrogen receptors were de-
tected in the vasculature of animals [26] and humans
[27,28]. The description of different subtypes of the estro-
gen receptor (estrogen receptor α and β) led to more spec-
ulations on cardiovascular estrogen effects in animals and
humans as well [1,29–32]. We therefore wanted to inves-
tigate whether the pure synthetic estrogen receptor antag-
onist 7 alpha- [9-(4,4,5,5,5-pentafluoropentylsulfinyl)
nonyl]estra 1,3,5(10)-triene-3,17 beta-diol (ICI 182,780)
[33] can modulate vascular estrogen effects.
Methods
In vitro model
A total of 7 mature female New Zealand White (NZW)
rabbits (Tierforschungszentrum, University of Ulm, Ger-
many) were benumbed by shooting a bolt into the back of
their heads and exsanguinated by cutting their carotid ar-
teries. The abdomen was opened with a scalpel and the
aortic vessel prepared by removal of the connective tissue.
Endothelium denudation of the abdominal and thoracic
aorta was then performed in all animals in situ with a 3F
Fogarty catheter (Baxter Inc., Unterschleissheim, Germa-
ny) which was pushed into the vessel through an incision
at the iliac bifurcation. After inflation with natrium chlo-
ride 0.9 % the balloon was pulled through the whole ves-
sel one time. The now denuded aortas were excised by
saving the adventitial tissue. Each aorta was cut into sec-
tions of 5 mm and these aortic rings were randomised into
14 groups. Three experimental test series were performed
(Table 1): 1) Effect of the pure synthetic estrogen receptor
antagonist ICI 182,780 (Schering, Berlin, Germany) at
concentrations of 20, 30 and 40 µM (n = 8 each). 2) Effect
of 40 µM 17β-estradiol (Sigma, Deisenhofen, Germany)
alone and in combination with 20 µM ICI 182,780, the
lowest concentration having been found to have no effect
on neointimal proliferation in test series 1 (n = 12 each).
3) Effect of 40 µM Daidzein (Sigma, Deisenhofen, Germa-
ny) and 20 µM Genistein (Sigma, Deisenhofen, Germany)
alone and combined with 20 µM ICI 182,780 (n = 10
each). These concentrations of 17β-estradiol, Genistein
and Daidzein have been demonstrated to be the lowest
concentrations with an inhibitory effect on neointima for-
mation previously (Figure 1) [25].
Control groups were held in medium containing 1 % iso-
propanol (Roth, Karlsruhe, Germany) and 1% dimethyl
sulphoxide (DMSO) (Sigma, Deisenhofen, Germany) be-
cause 17β-estradiol, Genistein and Daidzein were dis-
solved in isopropanol and DMSO of the same
concentration. All aortic rings were held separately in six-
well plates for 21 days at 37°C with phenol red free Dul-
becco's modified Eagle medium (DMEM) with Ham's F12
(mixed 1 plus 4; Gibco, Eggenstein, Germany), containing
D-glucose (4.5 g/l), 15 % fetal calf serum (fcs) (Bio Whit-
tacker, Heidelberg, Germany) and 2,5 ml/l Penicillin-
Streptomycin (Gibco, Eggenstein, Germany). The medi-
um contained 1 % isopropanol and 1 % DMSO in all
groups and was renewed together with the estrogens three
times a week.
After 21 days of treatment the sections were rinsed with
PBS buffer (Dulbecco's PBS, Gibco, Eggenstein, Germa-
ny), 500 ml PBS buffer containing 5 ml PBS+ basic-solu-
tion with calcium chloride dihydrate an magnesium
chloride hexahydrate (Sigma, Deisenhofen, Germany).
Immunohistochemistry, morphometry, statistical 
evaluation
The sections were fixed in 4 % formaline, embedded in
paraffin, and serially cut (4 µm slices) until the maximal
thickness of the neointima was reached. Haemalaun and
Eosin staining was performed for a first morphological
analysis. To identify smooth muscle cells and myofibrob-
lasts among medial and neointimal cells immunohisto-
chemical staining (biotin avidin peroxidase method) was
performed with a monoclonal antibody against α-actin
(mouse-anti-human; Renner Inc, Darmstadt, Germany).
Elastica-van-Gieson's staining was performed for the mor-
phometry of the neointima and media (software package
from Bilaney Consulting Inc, Düsseldorf, Germany). The
neointimal area was defined the area between lamina
elastica interna and lumen. The media area was definedBMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/13
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the area between lamina elastica interna and externa. His-
tomorphometry was done in a blinded fashion. The effect
on neointima formation is expressed as the neointima/
media ratio (median and 1st/3rd quartile). The Wilcoxon
two-sample test was used to determine statistical signifi-
cance at a level of p = 0.05.
Results
Morphoplogical aspects
Aortic rings were morphologically intact after 21 days of
cultivation and treatment as seen by microscopy. The lam-
ina elastica interna and externa was intact as well. The me-
dia area (area between lamina elastica interna and
externa) contained vascular smooth muscle cells which
were made visible by α-actin staining. Sections had differ-
ent amounts of neointima formation that contained vas-
culars mooth muscle cells surrounded by connective
tissue (Figure 2).
Effect of ICI 182,780 on post injury neointima formation
Administration of ICI 182,780 in concentrations of 20, 30
and 40 µM did not cause a significant (p = 0.05) effect on
post injury neointima formation (neointima/media-ra-
tio) over 21 days (Figure 3). Regarding the highest con-
centration of 40 µM ICI 182,780 treatment the p-value
did only reach 0.0875 which was in part due to the wide
range of the measured data.
Figure 1
Inhibitory effect of 17β-estradiol (E), genistein (G) and daidzein (D) on post-injury neointima development in concentrations
of 20/30/40 µM, compared to endothelium balloon denuded (BD) controls (C) (mean ± SD). The medium of all groups con-
tained 1 % isopropanol (1 % iso) and 1 % DMSO. Compared with controls 17β-estradiol, genistein, and daidzein (*) reduced
neointima formation significantly (p = 0.05) in a concentration dependent manner. Data from Finking et al., 2000 [25].
Table 1: Study Protocol
Goup 1st series 2nd series 3rd series
Control Control group Control group Control group
Treatment 20 µM ICI 182,780 20 µM ICI 182,780 20 µM ICI 182,780
Treatment 30 µM ICI 182,780 40 µM 17β-estradiol 20 µM genistein
Treatment 40 µM ICI 182,780 40 µM 17β-estradiol + 20 µM ICI 182,780 20 µM genistein + 20 µM ICI 182,780
Treatment 40 µM daidzein
Treatment 40 µM daidzein + 20 µM ICI 182,780
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Effect of 17β-estradiol on post injury neointima formation
Treatment with 40 µM 17β-estradiol over 21 days (Figure
4) resulted in a significant (p < 0.0001) reduction of post
injury neointima formation (neointima/media-ratio).
Treatment with 20 µM ICI 182,780 alone did not have an
effect. Additional treatment of 20 µM ICI 182,780 with 40
µM 17β-estradiol treatment did not result in a significant
reduction of the 17β-estradiol effect.
Effect of the phytoestrogens genistein and daidzein on 
post injury neointima formation
Treatment with 20 µM Genistein resulted in a significant
(p = 0.0083) reduction of post injury neointima forma-
tion (neointima/media-ratio) after 21 days (Figure 5).
This effect was not modulated by additional treatment
with 20 µM ICI 182,780. However, treatment with 40 µM
daidzein did not result in a statistically significant neointi-
ma formation (p = 0.0637) in this experiment. Additional
treatment with 20 µM ICI 182,780 also did not cause a
significant effect.
Discussion
The purpose of this in vitro experiment was to investigate
whether inhibitory estrogen and phytoestrogen effects on
post injury neointima formation, as demonstrated previ-
ously [22–25], can be influenced by the pure synthetic es-
trogen receptor antagonist ICI 182,780. Because aortic
rings from the whole aortic tree were used as target organs
and because the lumen diameter varies between different
aortas and parts of the aortic tree (thoracic and abdominal
aorta), the neointima-/media-ratio was calculated as the
basis for statistical analysis. In a first step the effect of dif-
ferent ICI 182,780 dosages from 20 µM to 40 µM was test-
ed. These dosages corresponded to estrogen and
phytoestrogen dosages that had been established as effec-
tive in this organ culture model before [25]. ICI 182,780
treatment in the three dosages did not cause a significant
effect on post injury neointima formation (neointima-/
media ratio). Focussing on neointima formation inde-
pendent from the media area (data not shown) there was
a statistically significant (p = 0,0392) inhibitory effect at a
concentration of 40 µM ICI 182,780. Because it has been
shown previously that ICI 182,780 at concentrations >50
µM directly affects the metabolism of 17β-estradiol it did
not make sense to use higher concentrations in this exper-
iment [34]. In order to investigate possible interactions
between an inhibitory estrogen/phytoestrogen effect on
post injury neointima formation and the estrogen recep-
tor antagonist, we used the lowest 20 µM concentration of
ICI 182,780 as tested before. Treatment with 40 µM 17β-
estradiol resulted in a significant reduction/inhibition of
post injury neointima formation. This inhibitory effect
was not influenced or modulated by additional treatment
with 20 µM ICI 182,780.
Treatment with 20 µM genistein reduced post injury ne-
ointima formation significantly. This inhibitory effect
could not be influenced by additional treatment with 20
µM ICI 182,780. The concentration of 40 µM daidzein did
not have an inhibitory effect on post injury neointima for-
mation, although this was demonstrated in previous ex-
Figure 2
Example for neointima formation in a female rabbit aortic
section after endothelial balloon denudation and 21 days of
cultivation in medium containing 1 % isopropanol and 1 %
DMSO. Staining with α-actin, magnification by lens × 20. Vas-
cular smooth muscle cells are stained in the medial tissue and
in the neointima.
Figure 3
The pure estrogen receptor antagonist ICI 182,780 in con-
centrations from 20 µM to 40 µM did not have a significant
effect (p = 0.05) on post injury neointima formation. Skeletal
Box-and-Whisker Plot showing (top down) maximum, 3rd
percentile, mean, median, 1st percentile and minimum.
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periments [25]. While a weak tendency of an inhibitory
effect was visible in this present experiment, speculations
may be allowed on the effect of higher concentrations of
daidzein. Additional treatment with 20 µM ICI 182,780
did not influence the daidzein effect.
Genistein is well investigated as an inhibitor of protein ty-
rosine kinases [20,21]. This may account for estrogen re-
ceptor independent antiproliferative properties.
Genistein's analogue daidzein lacks tyrosine kinase activ-
ity which could explain the different effects in our experi-
ment [21,35,36].
On the base of this presented data the inhibitory estrogen
effect of both, 17β-estradiol and the phytoestrogens, is
unlikely mediated by estrogen receptor pathways. Our
data support observations from experiments with female
mice which were deficient of one of the two known estro-
gen receptor (ER) subtypes α or β. Physiologic levels of
17β-estradiol, when compared with ovariectomized ani-
mals, were able to reduce neointimal proliferation after
vascular injury in both, ER-a [37] and ER-β [38] deficient
mice. Moreover, our data support findings from Dubey et
al. who demonstrated that phytoestrogens like genistein
and daidzein were able to inhibit human aortic smooth
muscle cell proliferation and migration by estrogen recep-
tor independent, i. e., mitogen-activated protein (MAP-)
kinase modulated pathways [39]. The authors, too, used
the synthetic ICI 182,780 for their control experiments.
ICI 182,780 was first introduced by Wakeling et al. [33]
and has been characterized as a competitive antagonists to
estrogens with high affinity to the estrogen receptor and
without a significant estrogenic activity itself.
But our data is in contrast to previous in vivo findings
from Bakir et al. [40]. The authors demonstrated an inhib-
itory ICI 182,780 effect on 17β-estradiol induced reduc-
tion of post injury neointima formation in rat carotid
arteries. However, another organ culture experiment (pul-
monary arteries from hypoxic rats) by Karamsetty et al.
demonstrated that 10 µM 17β-estradiol, 30 µM genistein,
and 30 µM daidzein enhanced the relaxation response to
carbachol. This was found to be a result of increased nitric
oxide synthesis and release. But this effect could not be
mediated by additional treatment with 10 µM ICI
182,780 [41]. The authors used estrogen and ICI 182,780
at concentrations comparable to our experiment. New
findings on slow genomic (transcriptional) and rapid
nongenomic (i.e., MAP kinase) estrogen effects [39,42,43]
and on different estrogen receptor subtypes (estrogen re-
ceptor α and β) [1–3] may lead to deeper insights into the
pharmacology of this system. Quite subtle ICI 182,780 ef-
fects on estrogen receptors could be demonstrated in spe-
cific cells of the sheep uterus [44] and in yeast genetic
systems [45]. The acute and rapid estrogen induced calci-
um-dependent release of NO could be blocked by ICI
182,780 in bovine aortic endothelial cells [46] and in a
human vascular endothelial cell (HUVEC) system [47].
The question remains which estrogen receptor independ-
ent mechanism(s) may have led to the demonstrated in-
Figure 4
17β-estradiol in a concentration of 40 µM caused a significant
(p < 0.0001) inhibition of post injury neointima development.
This effect was not modulated by additional treatment with
20 µM of the pure antiestrogen ICI 182,780. Skeletal Box-
and-Whisker Plot showing (top down) maximum, 3rd per-
centile, mean, median, 1st percentile and minimum.
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Figure 5
Treatment with genistein 20 µM (p = 0.0083) but not with
daidzein 40 µM (p = 0.0637) caused a significant inhibition of
post injury neointima formation. Additional treatment with
20 µM of the pure antiestrogen ICI 182,780 did not have a
significant (p = 0.05) modulating effect. Skeletal Box-and-
Whisker Plot showing (top down) maximum, 3rd percentile,
mean, median, 1st percentile and minimum.
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hibitory estrogen/phytoestrogen effect on post injury
neointima formation in our present experiment. Dubey et
al. were able to demonstrate that not 17β-estradiol but en-
dogenous metabolites like methoxyestradiols, with no af-
finity to estrogen receptors, could be responsible for ER-
independent antimitogenic effects on vascular smooth
muscle cells [48]. Metabolites like 2-methoxyestradiol
and 2-hydroxyestradiol were more potent than was 17β-
estradiol in inhibiting DNA synthesis, collagen synthesis,
cell proliferation and migration [34]. Cytochrome-P450
played a key role in this local estrogen metabolism and
ICI 182,780 at concentrations >50 µM inhibited this me-
tabolism. In addition, other nongenomic, i.e., antioxidant
mechanisms have to be discussed. Yoon at al. demonstrat-
ed inhibitory 17β-estradiol effects on vascular smooth
muscle cell proliferation (VSMC from rats) induced by
lysophosphatidylcholine (component of oxidized LDL)
or reactive oxygen species (ROS) [49]. The inhibitory 17β-
estradiol effect was not antagonized by ICI 182,780. Fur-
thermore, calcium antagonistic gender independent prop-
erties have been described for 17β-estradiol [15,16] and
for several phytoestrogens [50].
Conclusions
The inhibitory effect of 17β-estradiol and the phytoestro-
gen genistein on post injury neointima formation has un-
likely been mediated by estrogen receptor dependent
pathways.
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